



**BAL PHARMA LIMITED**

Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099  
 Phone : 080 41379500 Fax : 080 22354057 email :secretarial@balpharma.com  
**STANDALONE/CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2016**  
 CIN: L85110KA1987PLC008368

(Rs in Lakhs except EPS dat

Sr. No:	Particulars	STANDALONE				CONSOLIDATED				
		Quarter ended		Year Ended	Quarter ended		Year Ended			
		30 Jun 16 Unaudited	30 Jun 15 Unaudited	31 Mar 16 Audited	30 Jun 16 Unaudited	30 Jun 15 Unaudited	31 Mar 16 Audited			
<b>PART I</b>										
1	<b>Income from Operations</b>									
a)	Net Sales/Income from operations (Net of Excise Duty)	4,292.40	4,052.59	5,362.25	19,416.15	4,396.64	4,055.24	5,388.13	19,482.16	
b)	Other Operating Income	65.20	74.13	93.11	349.50	65.20	74.13	93.11	349.50	
	<b>Total Income from Operations (net)</b>	<b>4,357.60</b>	<b>4,126.72</b>	<b>5,455.36</b>	<b>19,765.65</b>	<b>4,461.85</b>	<b>4,129.37</b>	<b>5,481.24</b>	<b>19,831.66</b>	
2	<b>Expenses</b>									
a)	Consumption of Raw Materials/ Packing Material	2,052.65	2,138.16	2,812.87	9,767.82	2,052.65	2,138.16	2,812.87	9,767.82	
b)	Purchase of Stock in Trade	174.33	139.95	273.50	738.67	180.18	141.26	275.02	757.75	
c)	Increase/(decrease in stock in trade and WIP	(120.31)	(183.65)	(4.14)	(37.72)	(127.50)	(183.65)	(11.71)	(47.48)	
d)	Employee Cost	945.26	790.41	938.84	3,567.19	1,031.14	805.57	1,039.92	3,734.55	
e)	Depreciation and amortisation expenses	149.32	159.57	224.38	697.42	150.05	160.36	225.36	700.90	
f)	Other Expenditure	961.59	902.68	1,131.92	4,015.79	992.73	911.14	1,181.89	4,133.73	
g)	<b>Total</b>	<b>4,162.83</b>	<b>3,947.12</b>	<b>5,397.37</b>	<b>18,749.16</b>	<b>4,279.24</b>	<b>3,972.84</b>	<b>5,523.35</b>	<b>19,047.27</b>	
3	<b>Profit from Operations before other Income, finance costs and Exceptional items(1-2)</b>	<b>194.76</b>	<b>179.60</b>	<b>57.99</b>	<b>1,016.48</b>	<b>182.60</b>	<b>156.53</b>	<b>(42.11)</b>	<b>784.39</b>	
4	<b>Other Income</b>	<b>77.36</b>	<b>16.54</b>	<b>42.39</b>	<b>149.61</b>	<b>77.36</b>	<b>16.54</b>	<b>24.09</b>	<b>128.33</b>	
5	<b>Profit before finance cost and Exceptional items (3+4)</b>	<b>272.13</b>	<b>196.14</b>	<b>100.38</b>	<b>1,166.09</b>	<b>259.96</b>	<b>173.07</b>	<b>(18.02)</b>	<b>912.72</b>	
6	<b>Finance Costs</b>	<b>193.57</b>	<b>130.02</b>	<b>209.22</b>	<b>647.66</b>	<b>193.62</b>	<b>130.03</b>	<b>209.26</b>	<b>647.77</b>	
7	<b>Profit after finance cost but before Exceptional items</b>	<b>78.56</b>	<b>66.12</b>	<b>(108.83)</b>	<b>518.44</b>	<b>66.34</b>	<b>43.04</b>	<b>(227.28)</b>	<b>264.95</b>	
8	<b>Exceptional items</b>	-	-	-	-	-	-	-	-	
9	<b>Profit/Loss from ordinary activities Before Tax (7-8)</b>	<b>78.56</b>	<b>66.12</b>	<b>(108.83)</b>	<b>518.44</b>	<b>66.34</b>	<b>43.04</b>	<b>(227.28)</b>	<b>264.95</b>	
10	<b>Tax expenses</b>	<b>19.40</b>	<b>17.86</b>	<b>68.50</b>	<b>237.83</b>	<b>19.40</b>	<b>17.86</b>	<b>69.68</b>	<b>239.01</b>	
11	<b>Net Profit / Loss from ordinary Activities after Tax</b>	<b>59.16</b>	<b>48.26</b>	<b>(177.34)</b>	<b>280.60</b>	<b>46.94</b>	<b>25.18</b>	<b>(296.97)</b>	<b>25.93</b>	
12	<b>Extra ordinary items</b>	-	-	-	-	-	-	-	-	
13	<b>Net Profit / Loss for the period</b>	<b>59.16</b>	<b>48.26</b>	<b>(177.34)</b>	<b>280.60</b>	<b>46.94</b>	<b>25.18</b>	<b>(296.97)</b>	<b>25.93</b>	
14	<b>Minority interest</b>	-	-	-	-	(3.63)	(1.92)	17.75	(114.60)	
15	<b>Net Profit / Loss after taxes and minority interest</b>	<b>59.16</b>	<b>48.26</b>	<b>(177.34)</b>	<b>280.60</b>	<b>50.56</b>	<b>27.10</b>	<b>(314.72)</b>	<b>140.53</b>	
14	<b>Paid-up Equity Share capital( face value of Rs 10 each )</b>	<b>1,417.24</b>	<b>1,287.24</b>	<b>1,287.24</b>	<b>1,287.24</b>	<b>1,417.24</b>	<b>1,287.24</b>	<b>1,287.24</b>	<b>1,287.24</b>	
15	<b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	-	-	-	-	-	-	-	-	
16	<b>Earnings Per Share (of Rs 10 each) (Not annualised )</b>									
a)	Basic	0.42	0.37	(0.14)	2.18	0.04	0.21	(0.24)	1.73	
b)	Diluted	0.42	0.37	(0.14)	2.18	0.04	0.21	(0.24)	1.73	

*Handwritten signature*

**PART II**

<b>A) Particulars of Shareholding</b>									
<b>1) Public shareholding</b>									
- Number of Shares	78,86,570	65,86,570	65,86,570	78,86,570	65,86,570	65,86,570	65,86,570	65,86,570	65,86,570
- Percentage of shareholding	55.65	51.17	51.17	55.65	51.17	51.17	51.17	51.17	51.17
<b>2) Promoters &amp; Promoter group Shareholding</b>									
<b>a) Pledged / Encumbered</b>									
- Number of Shares	-	-	-	-	-	-	-	-	-
- Percentage of shareholding	-	-	-	-	-	-	-	-	-
<b>b) Non-encumbered</b>									
- Number of Shares	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%
- Percentage of shareholding (as a % of total share capital of the company)	44.35	48.83	48.83	44.35	48.83	48.83	48.83	48.83	48.83

**PART III**


**B Investor Complaints**

Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

**Notes:**

- 1 The above unaudited financial results as reviewed by the Audit Committee were approved by the Board of Directors at its meeting held on 10.8.2016.
- 2 Statutory Auditors have conducted Limited Review on the unaudited financial results for the quarter ended 30.06.2016.
- 3 Previous year figures were regrouped/rearranged to conform to the classification of current year.
- 4 As the Company deals with single product i. e pharmaceuticals, segment wise figures are not furnished.

Bangalore  
10 Aug 16

By the order of Board of Directors  
  
Shailesh Siraya  
Managing Director.